EBS Q1 2019 Earnings — Emergent BioSolutions Inc. Revenue & Financial Results | Market Cap Arena

EBSEmergent BioSolutions Inc.

$433M

Q1 2019 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$191M+61.8% YoY

Gross Profit

$53M27.6% margin

Operating Income

-$27M-14.3% margin

Net Income

-$26M-13.6% margin

EPS (Diluted)

$-0.51

QoQ Revenue Growth

-29.6%

Cash Flow

Operating Cash Flow

$105M

Free Cash Flow

$83M

Stock-Based Comp.

$7M

Balance Sheet

Total Assets

$2.2B

Total Liabilities

$1.2B

Stockholders' Equity

$988M

Cash & Equivalents

$137M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$191M	$118M	+61.8%
Gross Profit	$53M	$34M	+53.2%
Operating Income	-$27M	-$10M	-186.3%
Net Income	-$26M	-$5M	-430.6%

Revenue Segments

Product

$153M80%

Contracts and Grants

$22M11%

Contract Development And Manufacturing

$16M8%

Geographic Segments

Non-US

$97M51%

UNITED STATES

$94M49%